比较过xbi和ibb 最后选了后者 纳斯达克上市的更有创新精神
比较过xbi和ibb 最后选了后者 纳斯达克上市的更有创新精神
原文摘要:
(1)Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors.
(2)The SPDR S&P Biotech ETF, an equal-weighted fund with broad industry exposure, presents an attractive investment vehicle to leverage these AI-driven changes.
(3)Despite recent downturns in the biotech sector and XBI's specific exposure to smaller, speculative biotech firms, long-term trends and AI advancements suggest a strong rebound.
(4)Anticipated improvement in the time and cost of drug discovery due to AI, coupled with easing capital market conditions, will drive small-cap biotech outperformance, an area XBI is heavily exposed.